VIVUS, Inc. Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017

CAMPBELL, CA -- (Marketwired) -- 08/22/17 -- VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that Seth H. Z. Fischer, Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017 at 2:15 pm ET in Boston. During this presentation, Mr. Fischer will give a corporate overview, review the Company's clinical and commercial product portfolio, and discuss recent efforts to obtain additional product candidates.

An audio webcast of the presentation will be available in the events and presentations section of the Company's investor relations website, or by clicking here.

About VIVUS

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2016 as filed on March 8, 2017, and as amended by the Form 10-K/A filed on April 26, 2017, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Mark Oki
Chief Financial Officer
oki@vivus.com
650-934-5200

Lazar Partners
Matthew Ventimiglia
mventimiglia@lazarpartners.com
212-599-1265

Source: VIVUS, Inc.

News Provided by Acquire Media

Close window | Back to top